Previous 10 | Next 10 |
Gainers: [[PRTA]] +35.6%. [[CRBP]] +30.0%. [[GPRO]] +6.8%. [[VYNE]] +5.7%. [[LOTZ]] +3.6%.Losers: [[CRUS]] -7.5%. [[RMBS]] -6.3%. [[STRO]] -6.0%. [[ALTR]] -5.4%. [[NERV]] -5.1%. For further details see: PRTA, RMBS, NERV and GPRO among after-hours movers
Are Robinhod Penny Stocks Still A Buy? Robinhood continues to captivate headlines & penny stocks are right up there with it. The mobile-first trading app has been the center of attention and scrutiny following last week’s events. With massive short squeezes from the likes...
BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today a...
VYNE Therapeutics ([[VYNE]] +3.6%) has closed its previously announced registered direct offering of 21.1M shares at $2.37/share, with net proceeds of $46.7M that will be used for working capital and general corporate purposes.Also, the Company raised an additional $34.3M of net proceeds from...
BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock a...
Shares of beaten-down biotech stock Vyne Therapeutics (NASDAQ: VYNE) jumped more than 30% higher on Jan. 25, 2021, in response to a relatively minor development for its new acne treatments. In a nutshell, the company executed a contract that could boost sales of its recently launche...
Repro Med Systems (KRMD) -18% on preliminary FY20 results and CEO transition.Sanchez Midstream Partners (SNMP) -17%.Express (EXPR) -16% as Wedbush sees company 'hemorrhaging cash'.Lipocine (LPCN) -14% on launch of public offering.Midatech Pharma (MTP) -10%...
BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of ...
Gainers: Aemetis (AMTX) +105%.Express (EXPR) +98%.MingZhu Logistics (YGMZ) +50%.TS Innovation Acquisitions (TSIA) +45%.IZEA Worldwide (IZEA) +43%.Orbital Energy (OEG) +36%.VYNE Therapeutics (VYNE) +35%.Accelerate Diagnostics (AXDX) +35%.Atossa Therapeutics (ATOS) +33%...
Gainers: VYNE Therapeutics (VYNE) +33%, Evolus (EOLS) +33%, Accelerate Diagnostics (AXDX) +32%, Atossa Therapeutics (ATOS) +29%, Bionano Genomics (BNGO) +27%.Losers: Neuronetics (STIM) -14%, Akerna (KERN) -10%, Precigen (PGEN) -9%,...
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...